AstraZeneca Pharma India discloses Crisil ESG rating of 57
AstraZeneca Pharma India received an ESG rating of 57 from Crisil ESG Ratings. The rating was assigned on August 24, 2026, based on public information. The company did not engage Crisil for the independent assessment. Disclosure was made to BSE and NSE under SEBI Regulation 30.
*this image is generated using AI for illustrative purposes only.
AstraZeneca Pharma India Limited disclosed an Environmental, Social, and Governance (ESG) rating of 57 assigned by Crisil ESG Ratings & Analytics Limited on August 24, 2026.
The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company notified both the BSE Limited and the National Stock Exchange of India Ltd regarding the rating.
Independent Assessment
Crisil ESG Ratings prepared the report independently using publicly available information. AstraZeneca Pharma India confirmed that it did not engage the rating agency for this assessment.
Tanya Sanish, Company Secretary & Compliance Officer, signed the disclosure letter dated August 24, 2026.
Historical Stock Returns for AstraZeneca Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.58% | -5.90% | -10.19% | -18.30% | -13.04% | +133.03% |
How might AstraZeneca Pharma India's ESG rating of 57 influence its ability to secure green financing or attract ESG-focused institutional investors in the coming fiscal year?
What specific operational or governance improvements is the company prioritizing to raise its ESG score above the industry average in future assessments?
Could this independent Crisil assessment trigger a re-evaluation of AstraZeneca's supply chain sustainability standards across its Indian manufacturing facilities?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
